NVS

Equity

Novartis AG

Health Care · Drug Manufacturers - General

$168.62

+168.62 (+0.00%)

Open

N/A

Day Range

$168.56 - $170.46

52W Range

$97.72 - $170.46

Volume

3M

Price History

Key Statistics

Market Cap

N/A

P/E Ratio

N/A

EPS

N/A

Dividend Yield

N/A

P/B Ratio

N/A

Payout Ratio

N/A

ROE

N/A

Debt/Equity

N/A

Latest News

Avidity (RNA) Moves Date for Shareholder Vote on Novartis Merger

Insider Monkey 2 hours ago

Analyst Optimistic on Terns (TERN) Citing Possible $4.8B Market for Upcoming Leukemia Drug

Insider Monkey 2 hours ago

Tariffs Influenced Novartis to Build Over 7 Plants in US, Trump Says

MT Newswires 5 hours ago

European Stocks Mostly Higher in Friday Trading; French GDP Growth Slows, Inflation Rises

MT Newswires 6 hours ago

Atrium Therapeutics Begins Operations With 2 Precision Cardiology Candidates

MT Newswires 8 hours ago

Fair Value Estimate

DDM Value

$104.82

60.9% overvalued

Growth: 6.0% | Req. return: 10%

Peers in Health Care

Symbol Name Price Mkt Cap Div Yield Change
ABT Abbott Laboratories $116.32 N/A 2.06% +0.00%
001540.KQ AHN-GOOK PHA $8,070.00 N/A 5.45% +0.00%
LLY Eli Lilly and Company $1,052.20 N/A 0.59% +0.00%
NVO Novo Nordisk A/S $37.46 N/A 4.49% +0.00%
EJG.F EBOS Group Ltd. R $11.70 N/A 5.14% +0.00%
5889.T JAPAN EYEWEAR HOLDINGS CO LTD $1,998.00 N/A 4.20% +0.00%
0332.KL TOPVISN $0.17 N/A 11.76% +0.00%
ABBV AbbVie Inc. $230.81 N/A 2.88% +0.00%

Community Sentiment

Sign in to vote

0% Bullish 0% Neutral 100% Bearish

0 votes

Discussion (0)

Sign in to join the discussion

Loading comments...

About Novartis AG

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

www.novartis.com →

Dividend Safety

Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.

55

Borderline

Based on 4 fundamental factors

~ Recent dividend growth (3 yr)

Analysis Tools

Sign in for analysis tools

Share